Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses new agents that were recently approved for multiple myeloma. 

Three drugs were FDA approved within 3 weeks â€” Darzalex (daratumumab), Ninlaro (ixazomib), and Empliciti (elotuzumab). Darzalex and Empliciti are antibodies, and Ninlaro is a proteasome inhibitor. 

The agents can be used as monotherapy or in combination with conventional therapy, Greenberger explains. They have also extended progression-free survival in patients with myeloma.

Articles

Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses new agents that were recently approved for multiple myeloma. 


Lee Greenberger on Newly Approved Drugs for Multiple Myeloma

Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses how the society contributes to blood cancer research.

The Leukemia & Lymphoma Society recently passed the $1 billion mark in research investment, Greenberger said. The society currently has 320 active programs available.

The journey from a laboratory discovery to a therapy that can control disease takes about 10 years. Sustained funding is needed in order to make progress in this field, Greenberger says, and the society’s volunteers, advocates, and cancer patients step up in order to make progress in the field happen.

To learn more about The Leukemia & Lymphoma Society, visit 

Lee Greenberger, PhD

Articles

Lee Greenberger on Newly Approved Drugs for Multiple Myeloma

Lee Greenberger Discusses Blood Cancer Research and the Leukemia and Lymphoma Society